Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing contact dermatitis risk among Manitoba workers in the Manitoba Occupational Disease Surveillance System.

Contact dermatitis·2024
Same author

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Acta ophthalmologica·2023
Same author

Subconjunctival Rituximab Administration for the Treatment of Scleritis.

Ocular immunology and inflammation·2022
Same author

Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis.

Ocular immunology and inflammation·2021
Same author

Recurrences of Scleritis after Ocular Surgery.

Ocular immunology and inflammation·2021
Same author

Current insights in the pathogenesis of scleritis.

Experimental eye research·2020

Related Experiment Video

Updated: Jun 27, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Intermediate uveitis: long-term course and visual outcome.

N Vidovic-Valentincic1, A Kraut, M Hawlina

  • 1Eye Clinic, University Clinical Centre, Grabloviceva 46, Ljubljana, Slovenia. vid.val@t-2.net

The British Journal of Ophthalmology
|December 11, 2008
PubMed
Summary
This summary is machine-generated.

Intermediate uveitis (IU) can lead to vision loss over time, but one-third of patients achieve long-term remission. Younger age at onset is linked to better remission chances in intermediate uveitis.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Related Experiment Videos

Last Updated: Jun 27, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Area of Science:

  • Ophthalmology
  • Immunology
  • Retinal Diseases

Background:

  • Intermediate uveitis (IU) is an intraocular inflammatory condition with variable long-term prognosis.
  • Understanding the long-term course and visual outcomes is crucial for patient management.

Purpose of the Study:

  • To investigate the long-term course and visual outcomes of intermediate uveitis (IU).
  • To identify factors associated with remission and vision loss in IU patients.

Main Methods:

  • Retrospective cohort study of 29 patients with intermediate uveitis (IU).
  • Minimum follow-up of 10 years at a tertiary referral center.
  • Analysis of visual acuity, causes of vision loss, and remission rates.

Main Results:

  • Legal blindness or visual impairment increased from 17% at onset to 28% at 10-year follow-up.
  • Macular edema, cataract, and vitreous opacities were primary causes of vision loss.
  • 34% of patients achieved remission for over a year, with a mean time-to-remission of 8.6 years.
  • Younger age at onset was associated with higher remission rates (p = 0.036).

Conclusions:

  • Approximately one-third of intermediate uveitis patients experience remission lasting over a year.
  • Younger patients with intermediate uveitis have a better prognosis for achieving remission.
  • Long-term monitoring is essential due to the progressive nature of vision impairment in some IU cases.